Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells
- PMID: 17272681
- DOI: 10.1124/mol.106.029702
Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells
Abstract
Antimicrotubule agents are commonly used chemotherapy drugs for the treatment of breast and other cancers. However, these agents have variable activity partly because of microtubule regulatory proteins. Stathmin, an 18-kDa phosphoprotein that promotes microtubule depolymerization, was found to be frequently overexpressed in breast cancer. We previously identified stathmin-mediated mechanisms of resistance to antimicrotubule agents, including altered drug binding and delayed transit from G(2) into M phase, where these agents are effective in disrupting microtubule dynamics. We hypothesized that by reversing stathmin-mediated depolymerization of microtubules or by promoting entry into mitosis, this could increase sensitivity to antimicrotubule agents in human breast cancer cells overexpressing stathmin. We found that targeting stathmin or wee-1 expression with RNA interference can induce microtubule polymerization and promote G(2)/M progression, respectively, and sensitize stathmin-overexpressing breast cancer cells to paclitaxel and vinblastine. Furthermore, targeting wee-1 led to the phosphorylation of stathmin, which is known to attenuate its activity. Therefore, these data suggest a novel approach to improving the efficacy of certain antimicrotubule agents against breast cancer by regulating the function of stathmin.
Similar articles
-
Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer.Cancer Res. 2002 Dec 1;62(23):6864-9. Cancer Res. 2002. PMID: 12460900
-
Anti-STMN1 therapy improves sensitivity to antimicrotubule drugs in esophageal squamous cell carcinoma.Tumour Biol. 2015 Sep;36(10):7797-806. doi: 10.1007/s13277-015-3520-1. Epub 2015 May 6. Tumour Biol. 2015. PMID: 25944168
-
Vinblastine differs from Taxol as it inhibits the malignant phenotypes of NSCLC cells by increasing the phosphorylation of Op18/stathmin.Oncol Rep. 2017 Apr;37(4):2481-2489. doi: 10.3892/or.2017.5469. Epub 2017 Feb 20. Oncol Rep. 2017. PMID: 28259950
-
Stathmin destabilizing microtubule dynamics promotes malignant potential in cancer cells by epithelial-mesenchymal transition.Hepatobiliary Pancreat Dis Int. 2014 Aug;13(4):386-94. doi: 10.1016/s1499-3872(14)60038-2. Hepatobiliary Pancreat Dis Int. 2014. PMID: 25100123 Review.
-
[Antimitotic agents].Gan To Kagaku Ryoho. 1997 Sep;24(11):1519-25. Gan To Kagaku Ryoho. 1997. PMID: 9309150 Review. Japanese.
Cited by
-
Long Noncoding RNAs in Taxane Resistance of Breast Cancer.Int J Mol Sci. 2023 Jul 31;24(15):12253. doi: 10.3390/ijms241512253. Int J Mol Sci. 2023. PMID: 37569629 Free PMC article. Review.
-
HMGA1 positively regulates the microtubule-destabilizing protein stathmin promoting motility in TNBC cells and decreasing tumour sensitivity to paclitaxel.Cell Death Dis. 2022 May 3;13(5):429. doi: 10.1038/s41419-022-04843-4. Cell Death Dis. 2022. PMID: 35504904 Free PMC article.
-
Simvastatin Downregulates Cofilin and Stathmin to Inhibit Skeletal Muscle Cells Migration.Int J Mol Sci. 2022 Mar 5;23(5):2848. doi: 10.3390/ijms23052848. Int J Mol Sci. 2022. PMID: 35269994 Free PMC article.
-
Intrinsic and Extrinsic Factors Affecting Microtubule Dynamics in Normal and Cancer Cells.Molecules. 2020 Aug 14;25(16):3705. doi: 10.3390/molecules25163705. Molecules. 2020. PMID: 32823874 Free PMC article. Review.
-
High-throughput, microscope-based sorting to dissect cellular heterogeneity.Mol Syst Biol. 2020 Jun;16(6):e9442. doi: 10.15252/msb.20209442. Mol Syst Biol. 2020. PMID: 32500953 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
